Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  132k   1k   141

4564.50
+36.20 (0.80%)
NSE: 29 Mar 4:00 PM

Price Summary

Today's High

₹ 4575

Today's Low

₹ 4522.95

52 Week High

₹ 4645.55

52 Week Low

₹ 3789.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

76011.65 Cr.

Enterprise Value

76186.55 Cr.

No. of Shares

16.65 Cr.

P/E

32.21

P/B

3.88

Face Value

₹ 5

Div. Yield

0.66 %

Book Value (TTM)

₹  1175.7

CASH

2030.5 Cr.

DEBT

2205.4 Cr.

Promoter Holding

26.7 %

EPS (TTM)

₹  141.72

Sales Growth

7.91%

ROE

9.26 %

ROCE

11.68%

Profit Growth

-25.76 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ

Index Presence

The company is present in 35 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.91%
3 Year10.68%
5 Year8.19%

Profit Growth

1 Year-25.76%
3 Year8.32%
5 Year3.24%

ROE%

1 Year9.26%
3 Year14.72%
5 Year11.91%

ROCE %

1 Year11.68%
3 Year16.02%
5 Year13.18%

Debt/Equity

0.1212

Price to Cash Flow

56.78

Interest Cover Ratio

59.5210526315789

CFO/PAT (5 Yr. Avg.)

1.27949717744282

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 26.7 0
Sep 2022 26.71 0
Jun 2022 26.71 0
Mar 2022 26.72 0
Dec 2021 26.72 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 59.5210526315789.
  • The Company has been maintaining an effective average operating margins of 20.1263120529199% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 83.8814291704526 days.
  • Company has a healthy liquidity position with current ratio of 2.23142710625134.
  • The company has a good cash flow management; CFO/PAT stands at 1.27949717744282.

 Limitations

  • The company has shown a poor profit growth of 8.31610650523851% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.6768114727991% for the Past 3 years.
  • The company is trading at a high PE of 32.21.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 3479.6 3668.7 3630.6 4880.3 3897.6
Total Expenditure 2865.6 2998.8 3051.1 3077.5 3222.5
Operating Profit 614 669.9 579.5 1802.8 675.1
Other Income 63 114.7 403.4 118 51.4
Interest 7.7 12.7 9.8 1.7 2.8
Depreciation 205.4 205.2 221.5 226.2 238.8
Exceptional Items 0 0 0 0 0
Profit Before Tax 463.9 566.7 751.6 1692.9 484.9
Tax 122.8 147 252.1 576.6 160.3
Profit After Tax 341.1 419.7 499.5 1116.3 324.6
Adjusted EPS (Rs) 20.5 25.22 30.02 67.09 19.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 9359.3 10625.5 11850.4 13349.1 14405.2
Total Expenditure 8086.7 8360.9 8980.8 10212.3 11811.1
Operating Profit 1272.6 2264.6 2869.6 3136.8 2594.1
Other Income 261.3 273.5 743.2 801.1 482
Interest 62.8 56.8 47.8 46.7 38
Depreciation 774.1 780.6 789.2 835 814.3
Exceptional Items 0 0 0 0 0
Profit Before Tax 697 1700.7 2775.8 3056.2 2223.8
Tax 130.1 423.4 -161.9 869.8 600.6
Net Profit 566.9 1277.3 2937.7 2186.4 1623.2
Adjusted EPS (Rs.) 34.15 76.95 176.76 131.39 97.55

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 83 83 83.1 83.2 83.2
Total Reserves 11724.8 12601.1 15108.8 16900.5 18253
Borrowings 488 345.4 19.3 17.7 19.7
Other N/C liabilities -8.5 138.7 -528.8 -186.9 75.2
Current liabilities 4719.9 3079.3 4180.5 4560.3 6045.1
Total Liabilities 17007.2 16247.5 18862.9 21374.8 24476.2
Assets
Net Block 4717.3 4682.7 4433.9 5844.3 6150.5
Capital WIP 675 400.1 384.1 877.1 1186.4
Intangible WIP 0 0 27.7 23.7 13.9
Investments 1953.7 1819.1 3367.1 3392.2 3018.7
Loans & Advances 620.1 407 542 293.2 409.8
Other N/C Assets 2.6 5.4 1.4 0.1 207.7
Current Assets 9038.5 8933.2 10106.7 10944.2 13489.2
Total Assets 17007.2 16247.5 18862.9 21374.8 24476.2
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 697 1700.7 2775.8 3056.2 2223.8
Adjustment 964.3 958.1 681.8 273.3 583.1
Changes in Assets & Liabilities 51.3 342.1 -1141.5 632.7 -979.4
Tax Paid -174 -238.8 -476.9 -448 -488.8
Operating Cash Flow 1538.6 2762.1 1839.2 3514.2 1338.7
Investing Cash Flow -1180.2 -546.5 -1689.2 -1453.6 -1990.1
Financing Cash Flow -304.4 -2223.1 -224.1 -794.3 505.5
Net Cash Flow 54 -7.5 -74.1 1266.3 -145.9

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 26.72 26.72 26.71 26.71 26.70
aps trust - - 20.64 20.63 -
aps trust (trustee... - - - - 20.62
kallam satish redd... - - - - 3.32
kallam satish redd... - - - 3.32 -
k.satish reddy (hu... - - 3.32 - -
gunupati venkatesw... - - - 1.53 -
gunupati venkatesw... - - 1.53 - -
gunupati venkatesw... - - - - 1.53
g.v.prasad 0.71 0.75 - - -
samrajyam reddy ka... 0.67 0.67 0.67 0.67 0.67
satish reddy kallam 0.61 0.61 0.54 0.54 0.54
anuradha gunupati - - 0.01 0.01 0.01
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 73.28 73.28 73.29 73.29 73.30
jp morgan chase ba... 13.31 14.35 - - -
jp morgan chase ba... - - - - -
life insurance cor... - - 6.04 7.58 8.95
life insurance cor... 4.44 - - - -
life insurance cor... - 4.44 - - -
first state invest... 3.24 3.24 - - -
first senter inves... - - 2.20 - -
oppenheimer develo... 3.19 - - - -
franklin templeton... 2.91 2.87 - - -
sbi mutual fund - - - - -
sbi-etf nifty 50 - - 2.63 2.63 1.57
first state invest... 1.17 1.55 - - -
reliance capital t... 2.08 2.57 - - -
franklin templeton... 1.83 2.29 - - -
aditya birla sun l... 1.75 2.23 - - -
reliance capital a... - - - - -
first sentier inve... - - - 2.20 2.20
government of sing... - - 2.03 - -
aditya birla mutua... - - - - -
icici prudential s... - - 1.87 1.46 1.05
aditya birla sun l... - - 1.90 1.56 -
nps trust-a/c hdfc... - - 1.57 1.80 1.89
government of sing... - - - 1.86 1.36
mirae asset mutual... - - - - -
franklin templeton... - - - - -
icici prudential l... - - 1.57 1.14 -
hdfc trustee compa... - - 1.19 1.16 1.36
icici prudential f... - 1.31 - - -
uti-mastershare un... - - 1.24 - -
mirae asset tax sa... - - - - -
dsp mutual fund - - - - -
teluk kemang inves... 1.21 1.21 - - -
nippon life india ... - - - - 1.16
uti mutual fund - - - - -
kuwait investment ... - - - 1.14 -
government pension... - - 1.13 1.01 1.06
hdfc life insuranc... - - - - 1.03
iepf 0.07 0.07 0.14 - -
investor education... - - - 0.14 0.14

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

DR. Reddy's Laboratories informs about allotment of ESOP21 Mar 2023, 1:19PM Dr Reddy's signs deal to divest certain non-core brands in dermatology to Eris Lifesciences16 Mar 2023, 4:17PM Dr Reddy's Laboratories’ arm recalling 4,320 bottles of Tacrolimus Capsules in US8 Mar 2023, 11:29AM Dr. Reddy’s Laboratories informs about investors conferences 28 Feb 2023, 10:44AM Dr. Reddy’s Laboratories’ arm inks pact to acquire Mayne Pharma’s U.S. generic prescription product portfolio 27 Feb 2023, 12:29PM Dr. Reddy’s Laboratories informs about press release27 Feb 2023, 9:42AM Dr. Reddy's Laboratories included in Bloomberg GEI 2023 for sixth consecutive year9 Feb 2023, 10:30AM Dr. Reddy's Laboratories informs about press release 27 Jan 2023, 3:07PM Dr. Reddy’s launches Difluprednate Ophthalmic Emulsion in US market27 Jan 2023, 12:30PM Dr. Reddy's Laboratories reports 75% rise in Q3 consolidated net profit27 Jan 2023, 10:40AM Dr.Reddy's Laboratories informs about disclosure25 Jan 2023, 4:29PM Dr. Reddy's Lab - Quaterly Results25 Jan 2023, 4:09PM Dr. Reddy's Lab - Quaterly Results25 Jan 2023, 4:09PM Dr. Reddy's Lab - Quaterly Results25 Jan 2023, 4:09PM Dr. Reddy’s completes full set of clinical studies of rituximab biosimilar for filing in U.S., Europe20 Jan 2023, 2:40PM Dr. Reddy’s Laboratories informs about press release20 Jan 2023, 9:48AM Dr Reddy's reduces price of cardiovascular drug ‘Cidmus’19 Jan 2023, 10:50AM Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer Products13 Jan 2023, 6:08PM Dr. Reddy's inks pact with Theranica 11 Jan 2023, 4:09PM Dr. Reddy’s Laboratories informs about disclosure 29 Dec 2022, 9:28AM Dr. Reddy's Laboratories completes Phase 1 study of proposed biosimilar of Tocilizumab20 Dec 2022, 11:51AM Dr.Reddy's Laboratories informs about press release19 Dec 2022, 1:49PM Dr. Reddy's Laboratories’ arm enters into agreement to sell certain assets, liabilities19 Dec 2022, 11:35AM Dr. Reddy’s Laboratories informs about asset purchase agreement of subsidiary company 17 Dec 2022, 10:49AM Dr Reddy's Laboratories informs about press release 16 Dec 2022, 4:19PM Dr. Reddy's Laboratories’ arm reports results of AUR101 in Phase II Study in Patients with moderate to severe psoriasis16 Dec 2022, 12:59PM Dr.Reddy's Laboratories informs about analyst meet7 Dec 2022, 11:34AM Dr. Reddy's arm recalls over 48,000 cartons of drug used to treat sneezing, runny or stuffy nose5 Dec 2022, 9:47AM Dr Reddy's Laboratories earmarks capex of around Rs 1,500 crore for FY237 Nov 2022, 11:19AM Dr. Reddy’s Laboratories informs about newspaper advertisement31 Oct 2022, 12:46PM Dr. Reddy’s Laboratories informs about link of audio recordings29 Oct 2022, 3:55PM Dr. Reddy's Laboratories reports 12% rise in Q2 consolidated net profit29 Oct 2022, 12:27PM Dr. Reddy's Lab - Quaterly Results28 Oct 2022, 4:23PM Dr. Reddy's Lab - Quaterly Results28 Oct 2022, 4:23PM Dr. Reddy's Lab - Quaterly Results28 Oct 2022, 4:23PM Dr Reddy's recalling Phytonadione Injectable Emulsion in US 25 Oct 2022, 10:09AM Dr.Reddy's Laboratories informs about notice of postal ballot22 Oct 2022, 11:08AM Dr.Reddy's Laboratories informs about earnings call 13 Oct 2022, 12:27PM WEF recognizes Dr. Reddy’s Hyderabad factory as part of Global Lighthouse Network11 Oct 2022, 4:15PM Dr Reddy's Laboratories informs about allotment under ESOP7 Oct 2022, 12:39PM Dr. Reddys Laboratories informs about details of loss of certificate 28 Sep 2022, 4:57PM Dr. Reddy’s Laboratories informs about investor meet27 Sep 2022, 12:24PM Dr. Reddy's lab launches Lenalidomide Capsules in US8 Sep 2022, 9:11AM Dr Reddy's Laboratories gets EIR for manufacturing facility in Andhra Pradesh26 Aug 2022, 10:39AM Dr Reddy's, Intercept Pharmaceuticals enter into settlement agreement19 Aug 2022, 4:42PM Dr. Reddy’s Laboratories informs about disclosure on related party transactions17 Aug 2022, 3:36PM Dr. Reddy's arm recalls 5,531 cartons of Lansoprazole tablets16 Aug 2022, 12:08PM Dr. Reddy's gets nod to sell investment in Imperial1 Aug 2022, 9:13AM Dr. Reddy’s Laboratories informs about newspaper advertisement30 Jul 2022, 3:21PM Dr. Reddy's enters into licensing agreement with Slayback Pharma30 Jul 2022, 9:34AM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1338.7 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.1212 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was -25.7592039831286 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 18.0080804154055 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a poor ROE of 9.26219686162625 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Dr. Reddy''s Lab

X